Wafa Wahbi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wafa Wahbi has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed Al-Samadi
Department of Oral and Maxillofacial Diseases, Clinicum, Faculty of Medicine, University of Helsinki, 00014 Helsinki, Finland
3 shared publications Katja Korelin
Department of Oral and Maxillofacial Diseases, Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland; Translational Immunology Research Programme (TRIMM), University of Helsinki, Helsinki, Finland
2 shared publicationsTuula Salo
2 shared publications- Abdelhakim Salem
Department of Oral and Maxillofacial Diseases, Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland
1 shared publication Ahana Kapuge Dona Varuni Yashodha Ratnayake
Department of Oral and Maxillofacial Diseases, Clinicum, Faculty of Medicine, University of Helsinki, Helsinki, Finland
1 shared publication- Aini Hyytiäinen
Department of Oral and Maxillofacial Diseases Clinicum, University of Helsinki Helsinki Finland
1 shared publication
Latest Publications
- Open Access
- 23 September 2025
- Published by Elsevier in Translational Oncology
- Vol. 62, 102541
The protective role of IL-17C in oral squamous cell carcinoma
- 23 September 2025
- Published by Elsevier in Translational Oncology
- Vol. 62, 102541
Open AccessThe protective role of IL-17C in oral squamous cell carcinoma
- Open Access
- 24 April 2023
- Published by Elsevier in Translational Oncology
- Vol. 33, 101677
Evaluation of in vitro and in vivo personalized cancer treatment assays for oral squamous cell carcinoma
- 24 April 2023
- Published by Elsevier in Translational Oncology
- Vol. 33, 101677
Open AccessEvaluation of in vitro and in vivo personalized cancer treatment assays for oral squamous cell carcinoma
- Open Access
- 4 August 2021
- Published by Wiley in European Journal of Oral Sciences
- Vol. 129 (6) , e12819
The effect of fascin 1 inhibition on head and neck squamous cell carcinoma cells
Fascin 1 plays important pro‐metastatic roles in head and neck carcinoma (HNSCC) migration, invasion, and metastasis. However, limited advancement in targeting metastasis remains a major obstacle in improving HNSCC patients’ survival. Therefore, we assessed the therapeutic potential of fascin 1 targeted inhibition and its potential prognostic value in HNSCC patients. Using in vitro and in vivo approaches, we investigated the effect of compound G2, a novel fascin 1 inhibitor, on HNSCC cells migration, invasion, and metastasis. High‐throughput screening (HTS) was used to assess cytotoxic activity of compound G2 alone or combined with irradiation. We also evaluated the prognostic potential of fascin 1 in HNSCC patients. Interestingly, compound G2 reduced carcinoma cells migration and invasion in vitro and inhibited metastasis in vivo. Moreover, HTS revealed a modest cytotoxic activity of the compound G2 on HNSCC cell lines. Irradiation did not synergistically enhance the compound G2‐mediated cytotoxic activity. Survival analyses showed that high fascin 1 immunoexpression, at the tumor invasive front, was associated with cancer‐specific mortality in the advanced stages of HNSCC. Collectively, our findings suggest that fascin 1 represents a promising anti‐metastatic therapeutic target and a useful prognostic marker in patients with HNSCC. Novel anti‐metastatic agents could provide a valuable addition to cancer therapy.
- 4 August 2021
- Published by Wiley in European Journal of Oral Sciences
- Vol. 129 (6) , e12819
Open AccessThe effect of fascin 1 inhibition on head and neck squamous cell carcinoma cells
Fascin 1 plays important pro‐metastatic roles in head and neck carcinoma (HNSCC) migration, invasion, and metastasis. However, limited advancement in targeting metastasis remains a major obstacle in improving HNSCC patients’ survival. Therefore, we assessed the therapeutic potential of fascin 1 targeted inhibition and its potential prognostic value in HNSCC patients. Using in vitro and in vivo approaches, we investigated the effect of compound G2, a novel fascin 1 inhibitor, on HNSCC cells migration, invasion, and metastasis. High‐throughput screening (HTS) was used to assess cytotoxic activity of compound G2 alone or combined with irradiation. We also evaluated the prognostic potential of fascin 1 in HNSCC patients. Interestingly, compound G2 reduced carcinoma cells migration and invasion in vitro and inhibited metastasis in vivo. Moreover, HTS revealed a modest cytotoxic activity of the compound G2 on HNSCC cell lines. Irradiation did not synergistically enhance the compound G2‐mediated cytotoxic activity. Survival analyses showed that high fascin 1 immunoexpression, at the tumor invasive front, was associated with cancer‐specific mortality in the advanced stages of HNSCC. Collectively, our findings suggest that fascin 1 represents a promising anti‐metastatic therapeutic target and a useful prognostic marker in patients with HNSCC. Novel anti‐metastatic agents could provide a valuable addition to cancer therapy.